Arrowhead, Ionis Sue Each Other Over Rare Fat Disorder Drugs (2)

Arrowhead Pharmaceuticals Inc. and Ionis Pharmaceuticals Inc. filed dueling lawsuits over rival therapies for a rare genetic disorder, with Ionis alleging patent infringement and Arrowhead asking a different federal court to rule its plozasiran drug doesn’t infringe.

Plozasiran, designed to lower fat levels in the blood and reduce pancreatitis risk, is a first-in-class RNA interference therapy built on Arrowhead’s proprietary Targeted RNAi Molecule—or TRiM—platform, according to Arrowhead’s complaint filed Wednesday in the US District Court for the District of Delaware. It seeks a declaratory judgment that plozasiran doesn’t infringe Ionis’ US Patent No. 9,593,333, and that the patent is ...